Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Has Consensus Target Price of $201.14 According to Analysts

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-four analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $201.14.

A number of analysts recently commented on NBIX shares. TD Cowen increased their price target on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Mizuho upgraded Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wedbush raised their target price on Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a research report on Monday, August 3rd.

Insiders Place Their Bets

In related news, insider David W. Boyer sold 826 shares of the business’s stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the sale, the insider directly owned 8,722 shares in the company, valued at approximately $1,373,278.90. The trade was a 8.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the sale, the chief financial officer owned 42,808 shares in the company, valued at approximately $6,729,417.60. The trade was a 5.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $2,310,886,000. Bank of New York Mellon Corp bought a new stake in Neurocrine Biosciences in the second quarter worth $117,827,000. Ieq Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth $107,914,000. Bank of America Corp DE bought a new stake in Neurocrine Biosciences in the second quarter worth $104,382,000. Finally, Man Group plc purchased a new stake in Neurocrine Biosciences during the second quarter valued at about $101,293,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $145.35 on Tuesday. The firm has a market cap of $14.77 billion, a price-to-earnings ratio of 20.10, a price-to-earnings-growth ratio of 0.64 and a beta of 0.40. Neurocrine Biosciences has a 52 week low of $122.14 and a 52 week high of $186.12. The firm has a 50-day moving average price of $146.49 and a two-hundred day moving average price of $147.45.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The firm had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the firm earned $2.04 EPS. The company’s quarterly revenue was up 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Neurocrine Biosciences will post 7.72 earnings per share for the current year.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Revenue and earnings exceeded expectations. Third-quarter revenue rose 41.3% year over year to $1.12 billion, above the approximately $1.04 billion analyst estimate. Adjusted earnings were $3.29 per share, surpassing consensus estimates ranging from $2.54 to $2.67 and increasing from $2.04 a year earlier. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales surpassed $1 billion for the first time. Management cited strong demand across its portfolio of medicines, led by continued momentum for INGREZZA, a treatment for tardive dyskinesia and chorea associated with Huntington’s disease. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: INGREZZA sales guidance was raised. Neurocrine increased its 2026 net sales outlook for INGREZZA to $2.90 billion-$2.925 billion, signaling confidence in demand and the company’s near-term growth trajectory. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Neutral Sentiment: Analyst commentary remains valuation-focused. Zacks highlighted NBIX as a strong value stock, while the earnings reports and call transcript provide additional detail on operating metrics and management’s outlook. The strong results may already be reflected partly in the valuation, leaving investors focused on sustained growth and future pipeline execution. Neurocrine Biosciences Q3 2026 Earnings Call Transcript

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.